ClinicalTrials.gg
RecruitingNCT07215364EX-AIUpdated Sep 10, 2026

Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors

An interventional study of Training program in Early-stage Breast Cancer, sponsored by Spanish Breast Cancer Research Group. Recruiting at 5 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Spanish Breast Cancer Research Group · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group — 4 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Spanish Breast Cancer Research Group.

Planned enrollment
22nd of 35
74 · median 103
Started
2026
with 1 other
No phase
Only one
of the 49
Registered
47th of 49
by date

Among the 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group, this one is the 22nd largest by planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2026, is the only one with no phase, and was the 47th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group, or all of them as a file.
02

Study summary

This is a national clinical trial (Spain), conducted in approximately 5 sites, where patients who agree to participate will be included in one of two exercise program groups: the experimental group (a combined resistance and aerobic exercise program) and the control group.

The study will begin with a pilot phase involving approximately 74 patients.

Approximately 37 patients in the experimental group will follow a 6-month training program consisting of exercise sessions three alternate days per week (combining resistance and aerobic exercise).

Approximately 37 patients in the control group will receive standard medical care. These patients will be provided with international exercise guidelines for cancer patients.

Patients will continue with their assigned physical activity intervention until the maximum number of months for the intervention, unacceptable toxicity, discontinuation of hormone therapy, or withdrawal of consent-whichever occurs first.

Read the detailed description

Study population:

The target population for randomization in this study includes women diagnosed with Hormone receptor (HR)+/Human epidermal growth factor receptor 2 (HER2)-negative- early-stage breast cancer (EBC) and who have already received between 10 and 18 weeks of an AI (with or without a LHRHa) before the randomization in the study. Those patients that are candidates to receive an adjuvant CDK4/6i should have initiated the treatment at least 6 weeks before the randomization in the study.

Study treatment:

Although patients should receive adjuvant ET (including an AI [steroidal inhibitors such as exemestane or non-steroidal inhibitors such as anastrozole or letrozole], with or without a CDK4/6i and with or without a LHRHa) to be eligible for this study, the clinical decisions concerning the optimum management strategy for a particular patient will be taken independently of and prior to any decision by the investigator to invite a patient to participate in the study and according to the approved product information, local treatment guidelines and/or routine clinical practice.

The EX-AI study has been developed to be pragmatic as it adheres to local guidelines for the use of ET in the adjuvant setting. There are no extra tests or assessments required as we allow patients management to follow the standard of care. The burden on patients is limited to completing the training program and questionnaires/scales. The diagnostic and monitoring procedures used do not introduce any risk or burden beyond those associated with routine clinical practice in Spain.

The study is mainly focused on the completion of physical activity interventions by patients and its effect on their QoL rather than the adjuvant treatment that they will be receiving.

Study duration:

The study start date is the date of the first site activation. It is estimated that the accrual will be completed in approximately 18 months. The end of study (EoS) date is the date of the last visit of the last patient (LPLV =last patient last visit), considering 6 months of the exercise program, and its potential extension for 6 additional months depending on the progress of the study and once the necessary funding for this extension has been obtained; in case it is extended, patients in both groups will be able to choose whether they would want to continue in the study for these additional 6 months follow-up. If the patients in the control group agree to continue, then they would have a passive follow-up (i.e., maintaining the same physical activity that they performed up to date). The patients in the experimental group that agree to continue would be able to choose to continue in the study through an active or passive follow-up; if they decide to continue in an active follow-up, then they would continue with the training program as previously performed; if they choose to continue in the passive follow-up on the contrary, then they would not continue with the training program as previously performed but would be encouraged to remain physically active considering international recommendations (like in the control group).The evaluation of the exploratory objectives will be independent of the EoS date.

03

Conditions studied

  • Early-stage Breast Cancer

Browse trials for

Keywords

  • early-stage breast cancer (EBC)
  • HR-positive
  • HER2-negative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written document (ICD) prior to any specific study procedures, showing patience, willingness and ability to comply with the physical activity program in the experimental group, and scheduled visits and study procedures in both groups.
  2. Patients ≥18 years of age at signing of ICD.
  3. Documented confirmed HR+/- invasive EBC, adequately treated according to standard clinical practice and with absence of any evidence of disease (loco-regional or at distance).

    HR and HER2 assessments are performed under institutional guidelines.

    • HR testing should utilize an assay consistent with the most recent American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) Guidelines.
    • HER2 negativity is determined as immunohistochemistry (IHC) score 0/1+ or negative by in situ hybridization (ISH) according to the recommendations of the most recent ASCO/CAP Guidelines.
  4. (ECOG) performance status (PS) of 0-2.
  5. Pre-, peri-, and women (as determined by the investigator and according to the institutional guidelines) that have already received between 10 and 18 weeks of an AI (with or without a LHRHa) before the randomization in the study and administered according to local guidelines.

    Note: Patients that are candidate to receive an adjuvant CDK4/6i will only be eligible if the CDK4/6i was initiated at least 6 weeks before the randomization in the study and administered according to local guidelines.

  6. Patients must have undergone adequate (definitive) loco-regional therapy (surgery with or without radiation therapy), with or without neo-/ systemic CT.
  7. Patients must have an adequate organ and bone marrow function according to the standard clinical practice and institutional guidelines.
  8. Patients must be able and willing to fill out repeated questionnaires on QoL, pain and fatigue, as well as to adhere to the physical activity program.
  9. Fluent Spanish language skills for the complete comprehension of the questionnaires.
  10. With the consent of the investigator for participation in physical training and considering the medical history of the patient.

Exclusion criteria

Exclusion Criteria:

  1. Patients have received less than 10 weeks or more than 18 weeks of an AI (with or without a LHRHa) before the randomization in the study.
  2. Patients that are candidate to receive an CDK4/6i initiated the treatment less than 6 weeks before the randomization in the study.
  3. Patients have musculoskeletal injuries.
  4. Patients have known significant heart disease (myocardial infarction, unstable angina, congestive heart failure, cardiomyopathy, etc.).
  5. Patients with weight over 150kg.
  6. Patients have any type of illness or mental condition that prevents or compromises the well-being of the patient or compliance with the procedures.
  7. Patients have any cardiovascular to physical training by the investigator.
  8. Patients have been performing supervised training, either aerobic and/or resistance training (at a gym [group or individual classes] or in a specific sport), at least 2 days per week in the past 6 months.
  9. No access and/or unable to manage the website and other digital tools (i.e. applications) for training sessions.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Approximately 37 patients in the experimental group will perform a 6-month training program consisting of exercise sessions 3 alternating days per week (combined resistance + aerobic exercise).

    Behavioral: Training program

  • No intervention
    Control group

    Approximately 37 patients in the control group will receive usual health care. This patients' group will be provided with the international exercise guidelines for cancer patients.

Interventions

  • BehavioralTraining program

    Training program consist on physical activity sessions (combined resistance plus aerobic exercises) that will be performed 3 times per week every-other-day.

06

What researchers measure

Primary outcomes

  1. Effect of a training program in quality of life questionnaire (QoL)-related to endocrine therapy

    To determine the changes from baseline in the QoL-related to endocrine therapy (ET) symptoms measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast Cancer 45 (EORTC QLQ-BR45) questionnaire (questions 54-56, 63-69). To calculate the scores for each desirable dimension Scoring Manuals will be followed. Summary statistics (mean, mean confidence interval (CI), standard deviation, median and range) of absolute scores and their changes from baseline will be summarized at each assessment time. The comparison between treatment groups will be performed using a linear mixed model. Patients will complete this questionnaire at at baseline and during physical activity intervention: 1.5, 3, 6 and 12 months.

    Time frame: Through study treatment, and average of 12 months

Secondary outcomes

  1. Change from baseline in global QoL

    It will be evaluated by the EORTC QLQ-C30 questionnaire (questions 29 and 30). The questionnaire employs twenty-eight 4-point Likert scales with responses from "not at all" to "very much" and two 7-point Likert scales for global health and overall QoL. For functional and global QoL scales, higher scores represent a better level of functioning and are converted to a 0 to 100 scale. For symptom-oriented scales, a higher score represents more severe symptoms. To calculate the scores for each desirable dimension Scoring Manuals will be followed. Summary statistics (mean, mean CI, standard deviation, median and range) of absolute scores and their changes from baseline will be summarized at each assessment time. The comparison between treatment groups will be performed using a linear mixed model. Patients will complete this questionnaire at baseline and during physical activity intervention: 1.5, 3, 6 and 12 months.

    Time frame: Through study treatment, and average of 12 months

  2. Aromatase inhibitor associated musculoskeletal syndrome (AIMSS)

    AIMSS will be assessed using the Brief Pain Inventory (BPI) scale. The BPI is a 14-item questionnaire developed for cancer patients to assess the worst pain, pain severity, and pain interference over the past week, reported on a scale of 0 to10. Worst pain is categorized as mild (score from 3 to 4), moderate (score from 5 to 7), or severe pain (score from 8 to 10). Pain severity is measured as the average of responses to questions on worst pain, average pain, least pain, and pain right now. Pain interference is the average of 7 interference items, such as walking, mood, and sleep. The BPI is the most common, valid, and reliable measure to assess joint pain in cancer survivors. Patients will complete this scale at baseline and during physical activity intervention: 1.5, 3, 6 and 12 months.

    Time frame: Through study treatment, and average of 12 months

  3. Fatigue

    Fatigue will be measured by the Brief Fatigue Inventory (BFI) scale, which is a one-dimensional questionnaire based on the Brief Pain Inventory (BPI) that assesses the severity and impact of oncologic pain. The BFI is a scale with 11 points (0 to 10), including a dichotomous question about whether the patient felt tired or fatigued in the last 7 days. For each question, 0 is considered "no fatigue" and 10 is "worst fatigue possible," except for the dichotomous question that is not scored. Among the other questions, 3 measures the severity of fatigue in the current, daily situations, and in the last 24 hours. Six questions measure the influence of fatigue in general activities. The total score is the average of all questions. According to the total score, fatigue is classified as mild (from 1 to 3 points), moderate (from 4 to 6 points), and severe (from 7 to 10 points). Patients will complete this scale at baseline and during physical activity intervention: 1.5, 3, 6 and 12 months.

    Time frame: Through study treatment, and average of 12 months

  4. Compliance to treatment

    Compliance to treatment will be recorded using the pill counting method and patient diary. Drug compliance is defined as the percentage of doses a study participant has taken (actual consumed dose) compared to the total number of doses prescribed by their physician. The prescribed total dose refers to the comprehensive quantity of medication that is intended to be administered to a patient over a designated treatment period.

    Time frame: Through study treatment, and average of 12 months

  5. Body composition

    Body composition will be measured by bioimpedance scale, which provides information about body composition. This test is performed with special scales (Tanita® or Omron®) which have metal plates to conduct a very low-intensity electric current that travels through the lower limbs, allowing for the assessment of their resistance. These scales show the amount of lean, muscle, and fat mass, water percentage, bone density, and basal metabolic rate based on sex, age, height, and the intensity of physical activity. Resistance depends on the amount of water present in the body, with a constant proportion in muscle mass. By relating this data to other factors such as age, sex, and height, muscle mass can be calculated. Fat mass = weight - muscle mass. This method considers all the fat in the body, including localized fat, with a margin of error of 3-5%.

    Time frame: Through study treatment, and average of 12 months

  6. Adherence to the physical activity program

    Adherence to the physical activity program will be recorded through the physical exercise professionals' assistance and assessment and through the virtual training platform "10 Mets".

    Time frame: Through study treatment, and average of 12 months

  7. Information on sexual relations: libido

    Libido will be evaluated through the specific questions 44, 45 and 46 included in the EORTC QLQ-BR45 questionnaire. To calculate the scores for each desirable dimension Scoring Manuals will be followed. Summary statistics (mean, mean CI, standard deviation, median and range) of absolute scores and their changes from baseline will be summarized at each assessment time. The comparison between treatment groups will be performed using a linear mixed model. Patients will complete this questionnaire at at baseline and during physical activity intervention: 1.5, 3, 6 and 12 months.

    Time frame: Through study treatment, and average of 12 months

  8. Information on sexual relations: body image

    Body image will be evaluated through the specific questions 39, 40, 41 and 42 included in the EORTC QLQ-BR45 questionnaire. To calculate the scores for each desirable dimension Scoring Manuals will be followed. Summary statistics (mean, mean CI, standard deviation, median and range) of absolute scores and their changes from baseline will be summarized at each assessment time. The comparison between treatment groups will be performed using a linear mixed model. Patients will complete this questionnaire at at baseline and during physical activity intervention: 1.5, 3, 6 and 12 months.

    Time frame: Through study treatment, and average of 12 months

  9. Information on sexual relations: vaginal dryness

    Vaginal dryness will be evaluated through the specific questions 70, 71, 72 and 73 included in the EORTC QLQ-BR45 questionnaire. To calculate the scores for each desirable dimension Scoring Manuals will be followed. Summary statistics (mean, mean CI, standard deviation, median and range) of absolute scores and their changes from baseline will be summarized at each assessment time. The comparison between treatment groups will be performed using a linear mixed model. Patients will complete this questionnaire at at baseline and during physical activity intervention: 1.5, 3, 6 and 12 months.

    Time frame: Through study treatment, and average of 12 months

  10. Cognitive impairment

    Cognitive impairment will be evaluated through the specific questions 20 and 25 included in the EORTC QLQ-C30 questionnaire. To calculate the scores for each desirable dimension Scoring Manuals will be followed. Summary statistics (mean, mean CI, standard deviation, median and range) of absolute scores and their changes from baseline will be summarized at each assessment time. The comparison between treatment groups will be performed using a linear mixed model. Patients will complete this questionnaire at at baseline and during physical activity intervention: 1.5, 3, 6 and 12 months.

    Time frame: Through study treatment, and average of 12 months

  11. The Number of Participants Who Experienced Adverse Events (AE) Related to Study Treatment

    Safety assessments will be performed at baseline and during the study: Vital signs assessments (blood pressure, pulse and body temperature), triplicate 12-lead electrocardiogram (as clinically indicated), laboratory assessments (Hemoglobin, white blood cells count, absolute neutrophils count, lymphocytes, platelets count, glucose, alkaline phosphatase, gamma glutamyl transferase, alanine aminotransferase, aspartate aminotransferase, total bilirubin, serum creatinine, sodium, potassium, cholesterol, triglycerides, uric acid, BUN), pregnancy test (as clinically indicated). AE grade will be defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 5.0. Safety will be assessed by the incidence of AEs by maximum grade of severity of NCI CTCAE version 5.0.

    Time frame: Through study treatment, and average of 12 months

  12. Tolerability to the treatment

    Tolerability will be assessed by incidence of treatment dose modifications, discontinuations due to AEs, number of administered cycles, dose intensity, etc.

    Time frame: Through study treatment, and average of 12 months

07

Study locations

3 of 5 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 20 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 10, 2025
StartActual
Jul 2, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2029
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07215364
Lead sponsor
Spanish Breast Cancer Research Group
Responsible party
Sponsor
First posted
Oct 10, 2025
Start date
Jul 2, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Sep 10, 2026

Study contacts

Study Project Manager
Contact
inicio_ensayos@geicam.org
+34916592870
Start-Up Unit Manager
Contact
inicio_ensayos@geicam.org
+34916592870
Study Director
study director · Hospital Universitario Clínico San Cecilio, Granada, Spain
Study Director
study director · Hospital Quirón Sagrado Corazón-Sevilla, Sevilla, Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion